China's Akeso jumps on progress of immunotherapy drug for cancer treatment
26/08/2026 03:33
BUZZ-China's Akeso jumps on progress of immunotherapy drug for cancer treatment ** Shares of China-based drug developer Akeso Inc 9926.HK jump 9% to HK$96.9, on track for the biggest one-day pct gain since June 29
** Stock hits the highest level since August 20 in the second gaining session
** Akeso says ivonescimab plus chemo meets primary endpoint with significant overall survival benefit versus durvalumab plus chemo in phase III clinical study for the first-line treatment of advanced biliary tract cancer
** The study met all key secondary endpoints of progression-free survival and objective response rate - Co
** YTD, stock down 14.8%, while Hang Seng Biotech Index .HSBIO up 15.7%
(Reporting by Donny Kwok)
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals